Best of ASCO - 2014 Annual Meeting

 

Welcome

Triple-Negative

Breast Cancer—Metastatic

2017 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase 1b study of safety and immune response to PVX-410 vaccine alone and in combination with durvalumab (MEDI4736) in HLA-A2+ patients following adjuvant therapy for stage 2/3 triple negative breast cancer.

Steven J. Isakoff

TPS1126

Association of a four-gene decision tree signature with response to platinum-based chemotherapy in patients with triple negative breast cancer.

Jelmar Quist

1006

Association of family history and location of BRCA1 and BRCA2 mutations in triple-negative breast cancer patients.

Yen Yen Tan

e12588

Beyond triple-negative breast cancer and African ancestry: Tumor phenotypes among internationally diverse patient populations.

Evelyn Mawunyo Jiagge

1101

BRAF: An emerging target for triple-negative breast cancer.

Joan Albanell

1099

Breast cancer molecular subtypes association with clinical outcomes and race.

Ramses F. Sadek

e12575

Combined peripheral natural killer (NK) cell and circulating tumor cell (CTC) enumeration to enhance prognostic efficiency in patients (pts) with triple-negative breast cancer (TNBC).

Xiao-ran Liu

1105

Do the efficacy of BP-C1 correlate to receptor status in patients suffering from metastatic breast cancer stage IV?

Stig Einride Larsen

e12581

Dynamic relationship between cycling kinetics of triple-negative breast cancer and tumor infiltrating immune cells.

Ishita Choudhary

1100

Efficacy and safety of eribulin in patients with metastatic breast cancer at early and late application: Real-life experience.

Valentina Manzyuk

e12579

Efficacy and safety of eribulin in patients with triple negative metastatic breast cancer: Real life experience.

Alexey Manikhas

e12580

Efficacy/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer: Phase I/II ECHO-202 study.

Alexander I. Spira

1103

Expression of androgen receptor and epidermal growth factor receptor in invasive breast cancer: A retrospective study of 1,438 patients from China.

Junqing Chen

e12587

Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO).

Nicholas C. Turner

1007

Genome-wide copy number analysis of cell-free DNA from patients with chemotherapy-resistant metastatic triple-negative breast cancer.

Daniel G. Stover

1092

Immune gene signatures in triple-negative breast cancers characterized by varying levels of chromosomal instability.

Balazs Gyorffy

1096

Immunohistochemical (IHC) sub-classification of 105 triple negative breast cancers (TNBC).

Marion Stacoffe

e12577

Influence of marital status on risk of mortality for 23,493 cases of triple negative breast cancer for four mutually exclusive race/ethnicities.

Carol Parise

1098

Investigating tumoral and temporal heterogeneity through comprehensive -omics profiling in patients with metastatic triple negative breast cancer.

Christopher Szeto

1093

LCCC 1525: Combination immunotherapy with cyclophosphamide plus pembrolizumab in patients with advanced triple negative breast cancer (TNBC).

Benjamin Garrett Vincent

TPS1125

Long term follow up of patients with locally advanced triple negative breast cancer treated with adjuvant high dose chemotherapy and autologous stem cell transplantation: A single center experience.

Sani Mohammed Bukari

e12590

LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).

Rebecca Alexandra Dent

1009

Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy.

Tiffany A. Traina

1089

Phase (Ph) 2 stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01.

Ayca Gucalp

1102

Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.

Sylvia Adams

1008

Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.

Sylvia Adams

1088

Phase I study of olaparib (O), in combination with oral cyclophosphamide (C), in patients (pts) with metastatic triple negative breast cancer (TNBC) and recurrent high grade serous ovarian cancer (OVCA).

Chee Khoon Lee

1104

Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173).

Robert Wesolowski

TPS1127

Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Antonino Musolino

1095

Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer.

Maryann J. Kwa

TPS1124

Prevalence of androgen receptors expression in triple negative breast cancer patients and its correlation with clinicopathological criteria: Our institutes experience.

Kamel Farag

e12584

Retinoblastoma (Rb) protein expression in triple-negative breast cancer.

Jaymin M Patel

1097

Safety and efficacy of eribulin in combination with gemcitabine in patients with advanced triple negative breast cancer.

Vasiliki Michalaki

e12578

The association between neutrophil to lymphocyte ratio and overall survival in patients with triple-negative breast cancer.

Dilan Anil Patel

e12591

Treatment patterns and associated adverse events among patients with metastatic triple-negative breast cancer.

Virginia G. Kaklamani

e12576

Treatment patterns in metastatic triple-negative breast cancer (mTNBC).

Shan Jiang

e12589

Triple negative breast cancer (TNBC): Analysis of age and stage distribution and survival between African American and Caucasian women in a predominant low-income population.

Sheeba V. Tano

e12586

Triple negative breast cancer: An Indian problem— Experience from a tertiary care oncology centre.

Sameer Gupta

e12583

Triple-NOTE (Triple Negative Outcome in ESME): Large recent real-world prognostic data on triple negative metastatic breast cancers (mTNBC).

Marie-Paule Sablin

e12592

Use of serial multi-template liquid biopsies in triple negative breast cancer monitoring.

Paul Y. Song

1091

Validity of 1% hormonal positivity cutoff by American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines at Georgia Cancer Center.

Houssein Talal Abdul Sater

1094

Whole exome sequencing of metaplastic breast cancer (MpBC): Effect of mutation status on survival.

Luis Baez Vallecillo

1090